Clinical Trials Logo

Interstitial Lung Disease clinical trials

View clinical trials related to Interstitial Lung Disease.

Filter by:

NCT ID: NCT04138173 Completed - Clinical trials for Interstitial Lung Disease

Enhancing Physical Activity in Patients With Interstitial Lung Disease

Start date: January 14, 2020
Phase: N/A
Study type: Interventional

The level of physical activity (PA) has been shown to be an important predictor for morbidity and mortality in patients with chronic respiratory diseases such as COPD and more recently Idiopathic Pulmonary Fibrosis. Physical inactivity is a common feature of patients with chronic respiratory diseases. Whereas pulmonary rehabilitation is known to result in benefits in exercise capacity, symptoms and quality of life, these gains will not automatically translate into increases in physical activity. Therefore, the present study aims to investigate the effect of a physical activity coaching program on the physical activity level of patients with interstitial lung disease.

NCT ID: NCT04061356 Completed - Lung Cancer Clinical Trials

Assessment of Exhaled Breath Condensate Hydrogen Peroxide (EBC H2O2) as Measured Using a New Device (Inflammacheck™) in Patients With Interstitial Lung Disease, Lung Cancer and Healthy Volunteers.

EXHALE 1B
Start date: October 30, 2018
Phase:
Study type: Observational

A cross-sectional study of EBC H2O2 levels, as measured by a novel device, 'Inflammacheck™', and other markers of disease severity in patients with ILD and Lung Cancer.

NCT ID: NCT03929120 Completed - Clinical trials for Interstitial Lung Disease

Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)

Start date: November 5, 2019
Phase: Phase 1
Study type: Interventional

Researchers are trying to find out more about the safety of a new treatment, Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) which is still experimental, for Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD).

NCT ID: NCT03729583 Completed - Clinical trials for Interstitial Lung Disease

The Effects of Breathing Retraining in Patients With Interstitial Lung Diseases

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

Breathing retraining has been reported to lead to improvements in dyspnoea and walking distance in chronic obstructive pulmonary disease (COPD) patients. Evidence regarding the effects of such an intervention in ILD patients is though lacking. In view of this, the aims of such a study were to identify whether breathing retraining led to better management of dyspnoea and improved walking distance in ILD patients.

NCT ID: NCT03641742 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Families-At-risk for Interstitial Lung Disease Study

FAR-ILD
Start date: January 15, 2018
Phase:
Study type: Observational

The interstitial lung diseases (ILDs) are a family of closely related lung conditions characterized by alveolar inflammation, injury, and fibrosis not due to infection or neoplasia. While previously considered to be rare, a recent nationwide study found that idiopathic pulmonary fibrosis (IPF), a fibrotic ILD with a median survival of only 3.8 years, affects nearly 0.5% of older adults in the U.S. While pirfenidone and nintedanib slow the progression of IPF, neither reverses fibrosis nor prevents progression of the disease,and no studies to date have tested interventions that prevent the development of fibrotic ILDs.

NCT ID: NCT03599414 Completed - Clinical trials for Interstitial Lung Disease

CASPA: CArdiac Sarcoidosis in PApworth

CASPA
Start date: June 29, 2017
Phase:
Study type: Observational

Sarcoidosis is a disease of unknown cause which affects adults of all ethnic backgrounds. Clumps of tissue called granulomas develop primarily in the lungs, but can damage other organs, especially the heart. Anecdotal evidence from autopsy studies suggests the heart is affected in up to 68% of patients, but there is much uncertainty about this figure. If undetected and untreated, it can lead to serious complications or even sudden death. The current recommendation is to perform heart tracings (ECG s) on all patients, but this detects fewer than half of those with heart involvement. Blood markers traditionally used to diagnose heart disease are unreliable, meaning there is no simple blood test in use. The investigators propose a study with three aims. Firstly, identify the true prevalence of heart disease by performing Magnetic Resonance Imaging (MRI) scans on a group of patients with newly diagnosed lung sarcoidosis. Those found to have heart disease will have specialist (but routine) electrical heart tests. Secondly, (and perhaps the most immediate and clinically relevant) to identify the best method of diagnosing heart involvement using a combination of three simple tests: advanced ECG, 24-hour continuous ECG and a new type of computerised ultrasound scan. Thirdly, to identify proteins in the blood that could be used to develop a simple blood test for heart involvement in patients with lung sarcoidosis.

NCT ID: NCT03516994 Completed - Parkinson Disease Clinical Trials

Reducing Disparities in the Quality of Advance Care Planning for Older Adults

EQUALACP
Start date: August 1, 2018
Phase: N/A
Study type: Interventional

This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community. The two approaches are a structured approach with an advance care planning conversation led by a trained person using Respecting Choices (First Steps) and a patient-driven approach which includes a Five Wishes advance care planning form written in plain language. The study will determine which approach is more effective at increasing advance care planning within each racial group and reducing differences between the two groups in advance care planning.

NCT ID: NCT03416075 Completed - Clinical trials for Mechanical Ventilation

Mechanical Ventilation in Interstitial Lung Disease

Start date: January 1, 2011
Phase: N/A
Study type: Observational

To identify risk factors for mortality in patients with interstitial lung disease receiving mechanical ventilation.

NCT ID: NCT03396120 Completed - Clinical trials for Pulmonary Hypertension

The FVC/DLCO Ratio is a Useful Predictor of Pulmonary Hypertension in Patients With Interstitial Lung Disease

Start date: February 2, 2017
Phase: N/A
Study type: Observational

Pulmonary hypertension (PH) is a common disorder among patients with interstitial lung disease (ILD). The symptoms are usually nonspecific and overlooked. Thus, a noninvasive screening modality is recommended for early detection of PH because of its potentially significant impact on treatment strategy and clinical outcomes. Objectives: To evaluate the usefulness of assessing forced vital capacity (FVC%), diffusion capacity of the lung for carbon monoxide (DLCO%), and FVC%/DLCO% ratio to predict pulmonary hypertension among patients with ILDs.

NCT ID: NCT03388580 Completed - Pneumonia Clinical Trials

Predictors for Bronchoalveolar Lavage (BAL) Recovery Rate Derived From Quantified Computed Tomography (qCT)

Start date: January 2017
Phase: N/A
Study type: Observational

Bronchoalveolar lavage (BAL) is an important diagnostic method. The percentage of fluid extracted after instillation (recovery rate) is crucial for following diagnostic tests. The investigators aimed to compare novel quantified airway parameters from pre-interventional lung computed tomography (CT) with recovery rates to find possible predictive markers.